Results 11 to 20 of about 64,866 (299)

One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA

Drugs in Context, 2014
Background: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of ...
Susan T Arthur, Joshua M Noone, Bryce A Van Doren, Debosoree Roy, Christopher M Blanchette   +4 more
doaj   +2 more sources

The prognostic significance of weight loss in chronic obstructive pulmonary disease‐related cachexia: a prospective cohort study [PDF]

Journal of Cachexia, Sarcopenia and Muscle, 2019
Background Cachexia is an important extra‐pulmonary manifestation of chronic obstructive pulmonary disease (COPD) presenting as unintentional weight loss and altered body composition.
Hoi Yee Kwan, Matthew Maddocks, Claire M. Nolan, Sarah E. Jones, Suhani Patel, Ruth E. Barker, Samantha S.C. Kon, Michael I. Polkey, Paul Cullinan, William D.‐C. Man   +9 more
doaj   +2 more sources

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease. [PDF]

Mol Oncol
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Park SS, An K, Kim G, Choi SN, Lee HK, Hur K, Jeong KS.   +6 more
europepmc   +2 more sources

Physical function endpoints in cancer cachexia clinical trials : systematic review 1 of the cachexia endpoints series [PDF]

, 2023
In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures.
Dolan, R., McDonald, J., Hjermstad, M, Jamal-Hanjani, M, Jakobsen, G., Arends, J, Arends, J., Sayers, J, Sousa, MS, Simpson, MR, Anker, S. D., Brown, L., Jamal-Hanjani, M., Balstad, TR, McDonald, J, Cancer Cachexia Endpoints Working Group,, Fraser, E, Anker, SD, Sayers, J., Laird, BJA, Vagnildhaug, O. M., Hjermstad, M., Solheim, TS, Griel, C., Kaasa, S., McMillan, D., Griel, C, Jakobsen, G, Dajani, O, Bye, A., Cancer Cachexia Endpoints Working Group, Solheim, T. S., Kaasa, S, Brown, L, Maddocks, M, Reid, KF, McMillan, D, Bye, A, Fraser, E., Maddocks, M., Grzyb, A, Balstad, T. R., Ottestad, I. O., Skipworth, RJE, Ottestad, IO, Philips, I., Vagnildhaug, OM, Reid, K. F., Dolan, R, Laird, B. J., Baracos, V, Fallon, M. T., Simpson, M. R., Philips, I, Souza e Sousa, Mariana S. de (R18695), Baracos, V., Grzyb, A., Dajani, O., Skipworth, R. J., Fallon, MT   +59 more
core   +1 more source

A systematic review examining the relationship between cytokines and cachexia in incurable cancer [PDF]

, 2022
Cancer cachexia is an unmet clinical need that affects more than 50% of patients with cancer. The systemic inflammatory response, which is mediated by a network of cytokines, has an established role in the genesis and maintenance of cancer as well as in ...
Laird, Barry J, Gallagher, Iain J, Paval, D Robert, Barry J. Laird, Skipworth, Richard J E, James McDonald, D. Robert Paval, the Caledonian Cachexia Collaborative, McDonald, James, Richard J.E. Skipworth, Iain J. Gallagher, Patton, Rebekah, Rebekah Patton   +12 more
core   +1 more source

Dystrophin glycoprotein complex dysfunction:a regulatory link between muscular dystrophy and cancer cachexia [PDF]

, 2005
Cachexia contributes to nearly a third of all cancer deaths, yet the mechanisms underlying skeletal muscle wasting in this syndrome remain poorly defined.
Butchbach, Matthew E R, Burghes, Arthur H M, Guttridge, Denis C, Sahenk, Zarife, Saji, Motoyasu, Acharyya, Swarnali, Ringel, Matthew D, Skipworth, Richard J E, Rafael-Fortney, Jill A, Wang, Huating, Ringel, Matthew D., Hollingsworth, Michael A, Carathers, Micheal, Fearon, Kenneth C H, Butchbach, Matthew E.R., Hollingsworth, Michael A., Muscarella, Peter, Guttridge, Denis C., Rafael-Fortney, Jill A., Skipworth, Richard J.E., Burghes, Arthur H.M., Fearon, Kenneth C.H.   +21 more
core   +1 more source

A prospective study examining cachexia predictors in patients with incurable cancer [PDF]

, 2019
© 2019 The Author(s). Background: Early intervention against cachexia necessitates a predictive model. The aims of this study were to identify predictors of cachexia development and to create and evaluate accuracy of a predictive model based on these ...
Strasser, Florian, Nabal, Maria, Solheim, Tora S, Laird, Barry J, Vagnildhaug, O. M., Solheim, Tora Skeidsvoll, Baracos, V. E., Kaasa, S., Vagnildhaug, Ola M, Brunelli, Cinzia, Hjermstad, Marianne J., Hjermstad, Marianne Jensen, Kaasa, Stein, Laird, Barry, Vagnildhaug, Ola Magne, Baracos, Vickie, Hjermstad, Marianne J, Solheim, T. S., Wilcock, Andrew, Solheim, Tora S.   +19 more
core   +1 more source

Inflammation in Cachexia

Mediators of Inflammation, 2015
Cachexia is a complex wasting syndrome associated with a marked detrimental effect upon life quality and survival in patients with cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure, AIDS, and chronic kidney disease, among other conditions. Its prevalence is of around 5 to 15% in cardiac patients at end stage, rising up to 30%,
Seelaender M., Busquets S., Laviano A., Püschel G., Margaria T., Batista M. L. Jr.   +5 more
openaire   +5 more sources

Cardiac cachexia

Annals of Medicine, 2004
Chronic heart failure (CHF) remains an important and increasing public health care problem. It is a complex syndrome affecting many body systems. Body wasting (i.e., cardiac cachexia) has long been recognised as a serious complication of CHF. Cardiac cachexia is associated with poor prognosis, independently of functional disease severity, age, and ...
Stefan D, Anker, Wolfram, Steinborn, Sabine, Strassburg   +2 more
openaire   +2 more sources

A multi‐targeted treatment approach to cancer cachexia: Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) trial [PDF]

, 2020
Background Cancer cachexia is a condition often seen at diagnosis, throughout anti-cancer treatments and in end-stage nonsmall- cell lung cancer patients.
Rita Sasidharan, Bird, Stephen P., Keogh, Justin W.L., Elaine S. Rogers, Rogers, Elaine S, Rogers, Elaine S., Matthew R. Wood, Stephen P. Bird, Roderick D. MacLeod, Bird, Stephen P, Joanna Stewart, Graeme M. Sequeira, Wood, Matthew R, Bruce Arroll, Arroll, Bruce, Sasidharan, Rita, Sequeira, Graeme M., Keogh, Justin WL, Stewart, Joanna, MacLeod, Roderick D, Justin W.L. Keogh, Wood, Matthew R., Sequeira, Graeme M, MacLeod, Roderick D.   +23 more
core   +1 more source